NEWSROOM

Phytanix Bio

Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential

Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential

NEW YORK and SANTA BARBARA, Calif., July 30, 2024 - Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck. The updated presentation provides an in-depth look at the company’s strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines. The...

read more
Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines

Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines

Phytanix Bio is a preclinical stage pharmaceutical company founded by former members and associates of GW Pharmaceuticals, holding exclusive cannabinoid and cannabinoid-like medicine intellectual property (IP) The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close The business combination is expected to be...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850